NEW YORK (GenomeWeb) – VolitionRx today announced it has closed its public offering of 2,475,000 shares of stock at an offering price of $3.75 per share for net proceeds of about $8.5 million.
The firm's stock began trading on the New York Stock Exchange MKT on Feb. 6, under the ticker symbol "VNRX."
The firm said it intends to use the proceeds to fund prospective colorectal trials with Hvidovre Hospital in Denmark and an ongoing study at University Hospital in Bonn, Germany, as well as for general working capital.
National Securities, a wholly owned subsidiary of National Holdings, and Lake Street Capital Markets acted as joint book-running managers for the offering. The Benchmark Company acted as co-manager for the offering.